fluorescent in-situ hybridization News
-
New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of a new study in the Journal of Molecular Diagnostics on the Idylla™ GeneFusion Assay (RUO) for rapid detection of targetable fusions involving ALK, ROS1, RET, and NTRK1/2/3 and MET exon 14 skipping mutations. The ...
By Biocartis NV
-
Agilent Technologies Expands Catalog of SureFISH Break-Apart Probes
Agilent Technologies Inc. (NYSE: A) today introduced SureFISH ALK, ROS1 and RET break-apart translocation probes, expanding its offering of oligonucleotide-based fluorescent in situ hybridization (FISH) products. Agilent now offers more than 450 FISH probes The majority of FISH probes available on the market use BAC technology. BAC probes target repeat regions, and probe choices are limited by ...
-
Agilent Technologies Joins Forces with Baylor College of Medicine to Provide Customized CGH Microarrays for Cancer, Prenatal and Postnatal Research
Agilent Technologies Inc. (NYSE: A) has announced it is collaborating with Baylor College of Medicine's Medical Genetics Laboratories to provide customized CGH (comparative genomics hybridization) microarrays to researchers worldwide. Six new microarray designs unite the power of Baylor's data-rich expertise in genetics research with Agilent's microarray manufacturing capabilities to enable ...
-
Agilent Technologies introduces next-generation fluorescent in situ hybridization assays for molecular analysis
Agilent Technologies Inc. (NYSE: A) today introduced Agilent SureFISH probes, the next generation of fluorescent in situ hybridization (FISH) assays, delivering a comprehensive menu of the industry's highest resolution probes for a wide range of molecular analysis applications. Agilent SureFISH probes deliver dramatically better performance compared to existing FISH products. SureFISH probes ...
-
Agilent Technologies SureSelect Target Enrichment Now Available for Ion Proton Next-Generation Sequencing Systems
Agilent Technologies Inc. (NYSE: A) today introduced a new SureSelect target enrichment solution that allows Ion Proton users to realize the full power of their next-generation sequencers with the industry's leading human exome and custom DNA target enrichment solutions. SureSelect target enrichment is now available for all major sequencing platforms, enabling researchers to achieve the ...
-
Agilent Technologies Introduces New Exome Optimized for Clinical Research Sequencing
Agilent Technologies Inc. (NYSE: A) today introduced the SureSelect Clinical Research Exome. The performance-optimized exome design was developed in collaboration with researchers from Emory University and the Children's Hospital of Philadelphia. SureSelect Human All Exon V5 was used as the core for the new design. Performance has been enhanced in disease-associated regions, providing 10 percent ...
-
Agilent Technologies, Cell Line Genetics Collaborate on High-Throughput Cell-Line Characterization Services for Regenerative Medicine, Cancer Researchers
Agilent Technologies Inc. (NYSE: A) today announced a collaboration with Cell Line Genetics, Inc., a leading provider of cell-line characterization and quality assurance services. CLG will develop high-throughput, genomic characterization workflows to confirm and monitor the integrity of cell lines for translational and regenerative medicine research. The workflows will be based upon Agilent's ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you